In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Maury Raycroft has given his Buy rating due to a combination of factors that highlight the promising potential of Taysha Gene Therapies. The company’s Rett gene therapy program has shown significant progress, with updated clinical data indicating continuous patient benefits over time, particularly with high-dose treatments. The analysis of milestone gains, although conservatively evaluated, suggests meaningful improvements in patient outcomes.
Furthermore, the deep reduction in the R-MBA rating scale was a positive surprise, showcasing the therapy’s impact on a well-developed and granular scale. The high interest from caregivers in participating in gene therapy trials also supports the potential for rapid enrollment in pivotal studies. Additionally, the robust biodistribution data from non-human primate studies further underscores the therapy’s potential efficacy, as evidenced by a 100% responder rate in clinical milestones related to motor skills and communication.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.